๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Eton Pharmaceuticals, Inc. (ETON)
NASDAQ: ETON ยท Real-Time Price ยท USD
62.18
-1.47 (-2.31%)
Nov 18, 2026, 12:45 PM EST - Market open
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

The strategy pairs a diversified ultra-rare disease portfolio and patient-access focus with lean operations and recurring launches. Q3 2026 revenue of $58 million reached the $200 million goal five quarters early; multiple pipeline launches and readouts are planned for 2027โ€“2028.

Operator

Hi, everyone. Good afternoon. Welcome to the 2026 Jefferies Healthcare Conference. Please welcome Sean Brynjelsen, CEO of Eton Pharmaceuticals. Thank you.

Sean Brynjelsen
CEO, Eton Pharmaceuticals

Thank you. Thank you, everyone, for attending today. I want to talk a little bit about Eton Pharma and what we do. It is actually pretty simple. Our company was founded in 2017, and at the time, we started out with a 505(b)(2) strategy, and about two years into that, decided to go all in on ultra-rare disease. We noticed that in the United States, there are over 7,000 rare diseases, and less than 5% of them have any type of cure, treatment. A lot of parents with children that were just not being served by big pharma. I saw this as a great opportunity because you ended up where these patients were largely being ignored, and I just thought, well, if all these patients are being ignored, why is that? They were being ignored because there were less than $50 million typically on a given product.

The market size was very small. Patient population might be 80 people, could be 12, could be a couple of thousand, but certainly far less than the FDA's definition of a rare disease, which is 200,000. For us, what this meant is you have this universe of products, you have a small patient base, mostly children, and you realize that there is thousands of these rare diseases with no treatment options. From my perspective, I thought we could build a unique business model. What we have done is we have proven that business model today. This is a business model that is unique. I think it took investors several years to figure that out, and the business model is to really build the largest ultra-rare disease portfolio in industry.

The second part of that was not just having the products, because having the products is one part, but getting the commitment to your patient in a way that was authentic and real, and unlike what big pharma does, where they tout all these wonderful programs you can apply through and jump through these hoops, but at the end of the day, the patient was not getting the product if they were not getting reimbursed or the insurance was not covering it.

So, I decided a long time ago that if these kids need drug, they are going to get drug. We are going to make sure that the patient access that we give is unprecedented, and that we have done through the Eton Cares program. You will find out a little bit more about that later in my presentation. And innovative therapies. Some of the therapies are more innovative than others.

I'll talk a little bit about the product portfolio. I'm proud of all of these products because they're meaningful products. They're products that, for these patients, we have worked very closely with the advocacy groups, we work very closely with the caregivers, and we listen to the doctors on what they need. I do want to emphasize that our approach to bringing these products to market is almost agnostic as to how we get those products to market. It doesn't matter whether we're buying them or licensing them, we're developing them, whether they're small molecule, whether they're big molecule, that's all irrelevant. The patient doesn't care about that. They care about, does the product work? Does it treat my given disease? Can I get access to it? It's as simple as that. What you have is a differentiated business model based on these four pillars.

Diversified portfolio focus. My dream on this company is to have all the large therapeutic areas covered with products, for us to have teams in each of these therapeutic areas. That's building a diversified portfolio of industries, of assets, which are contrary to a typical industry approach, which is to say, we're going to be in endocrinology. We're going to be the best in endocrinology. We want to build up. It's not in endocrinology, we don't want to be there. We want to focus on blockbuster products. If you look at most of the biotech companies out there, they're story stocks. If X, Y, and Z happens, we got this billion-dollar market ahead of us. X, Y, and Z rarely happens.

One of the aspects of this was to ensure that when we brought products to market, we would be able to do so with a high degree of certainty. Every product and project that we have done, we have brought that product to approval, whether that was partnering or whether that was internally developed. We have a unique growth engine, which is unlike any other. We have a track record of success with doing M&A and licensing. We today have more inbound licensing deals and transaction deals than I've ever seen. In fact, probably more than we can even contemplate. Part of that, I guess, is as you move into different therapeutic areas, you're going to get a lot of that in.

We do have to go through and figure out which ones are going to make a strategic fit, and I'll talk a little bit about how we select those deals. In conjunction with that, we end up having a number of internally developed products that emanate from parents' desires, physicians' desires, patient advocacy groups, which come up with ideas. We go to the agency, we work very closely with the FDA, and we think we can launch four products next year. When I say four products, I mean more than four products. This year, we launched three products. Previous year, we launched three products. We're on set to launch four or more products next year. The other aspect of this, as I touched on, was therapeutic area agnostic.

If there's a rare disease, ultra-rare disease product, why do I need to be locked into a given therapeutic area? Today, we're in multiple therapeutic areas. We're in metabolic, we're in endocrinology, we're in hematology. We just went into infectious diseases, the launch of IMPAVIDO. We just also now entered neurology with our licensing deal of LIBERVANT, which we are very excited about, and we think is going to be a fantastic product for patients. The other aspect of this, the final pillar of this, I guess you could say this table, is a lean operating model. I was talking to a CEO of a company recently, and he's like, "Well, how do you guys launch all these products with so few people?" My response to him was, well, why do you have so many people to launch one product? It's not necessary.

If you have the right people, and we think we have the best in the business, you can launch products because people know what they're doing. We've launched many products before. I have our Chief Commercial Officer, the team we hire, we go out and we try to find the people that know what they're doing. At that point, it's with a patient focus in mind at the end of the day. That's what I care about beyond everything else. We have one of the broadest rare disease portfolios in industry. 12 approved products, six therapeutic areas. I'm not that excited by this chart. Some people would be. I just feel like there's so much more work to be done. I think that there'll come a day when we'll have 100 products up here.

If we keep growing and launching three, four products a year-over-year, which we will do, and we will largely even potentially do larger acquisitions, we will be in 12 different therapeutic areas. There is no reason we can't build this out. This is an infrastructure. It's a business strategy. This isn't a story stock where you're investing in because they're going to get this clinical result or they're going to have this inflection point. Don't ever invest in the company if you're looking for an event-driven stock . This company is really something that you should be comfortable investing in and sitting on it for 10 years and coming back and being really happy with the return. The return and the investors is not why we're doing what we're doing.

We're doing this for the patients at the end of the day, and that's all a side effect of launching products on a year-over-year basis. I'm very excited about ET-900. This is a product that is actually, will be a spinoff of INCRELEX. They're in totally two different areas. INCRELEX is for a growth hormone disorder. There's only a couple hundred patients in the United States on that product, but some doctors from Baylor University and University of Chicago noticed that it has a mechanism of action to address infantile spasms, which is a severe neurological issue in babies primarily. These babies have 70 seizures a day. In the animal models, INCRELEX worked fabulously in terms of stopping those seizures.

We have now started a clinical study to expand the use of IGF-1 replacement therapy, and that will be our ET-900, and we hope to have clinical results announced in the first half of next year. That would be fantastic. I will not go into all the disease details. We do not have a lot of time to do that, but I do want to touch on that. The other products, I think the idea here that I am trying to convey is that when we entered neurology, we did not want just one trophy product, LIBERVANT, sitting in neurology, say, we are in neurology. What we do is we want to build out that portfolio in each of these segments. You want to build out a business. I have got a general manager that is in charge of endocrinology. Think of that like a company.

She runs it, she has got people, so on and so forth. We have our back office support that handles all of it in terms of the quality, the regulatory, the logistics, but the sales, the marketing, the commercialization, these are different buckets. We took neurology and we added ET-900 into that. Similarly, when we bought GALZIN from Teva, this was a Wilson disease drug. It is a copper storage issue. Many of the patients were non-compliant because it causes GI discomfort, GI issues. If you had to take a medicine that was going to make you nauseous, how likely would you be to skip a dose? Probably pretty likely. This is three times a day. We decided, let us do a sustained release, a controlled release drug that will be done in the morning when you wake up and before you go to bed, and that is it.

It will also alleviate the side effects. We did a study on ET-700. The side effects were basically no different than placebo, which we were really happy to see. The efficacy was much better than placebo, not quite as good as GALZIN, so we are continuing that study because we had an eight-hour release profile on that product. We are now going to do a two and a four-hour. Most of the action is in the small intestine, which is about a three-hour period between stomach and through the small intestine. We think that two to four-hour range is going to be spot on. I am very confident that that will have a successful outcome, and we hope to announce results later in 2027. I could go on, but maybe I will touch on one more, HEMANGEOL. HEMANGEOL is for hemangiomas.

If some of you have seen children, sometimes they are born with a red mark, and we call it a strawberry mark or something of that nature, and it can be of various sizes. It can be the size of a quarter, or it could be over the entire arm. I have seen severe cases where it is over the entire face, could cause issues with sight. Having HEMANGEOL, which is a systemic therapy, it uses a molecule called propranolol, to me, at least, it looks miraculous, because if you look at the before and after pictures of some of these children, it is amazing how well that works. However, doctors are not exactly thrilled to be giving systemic therapy to an infant. They used off-label timolol, which is an ophthalmic solution, to treat the hemangioma when they were smaller.

What we found is after we did the Hemangeol deal, we were able to in-license an R&D project, ASN-001, which is a topical timolol gel. Very high efficacy, clinical studies done, NDA virtually complete. We got to run one PK study to kind of get that final piece, and then we'll file that NDA in the middle of next year. About 80% of children with hemangiomas would qualify for ASN-001. Only 10% really qualify for Hemangeol, which is for the really severe cases. The ASN product will be a big product launch, we believe, in 2028. Will drive a lot of growth from a revenue perspective, but more importantly, for these patients which need it. I co-founded the company in 2017. We didn't go back that far because it would have just been a bunch of zeros. We ended up starting with 2021.

We had $3 million in cash, and we built up the company, as you can see, quite nicely. It's interesting, as we've gotten bigger, our growth has actually accelerated. It hasn't even slowed down. We end up with a pretty good revenue growth from 2026. 2027, it will be far greater. We haven't given guidance on that, so stay tuned. I will eventually. We have been mostly conservative in the guidance that we give the street, so you'll notice if you look historically that we typically will understate what we can do. We don't understate it purposely, but we understate it just to be conservative, knowing that not everything always goes according to plan. Fortunately, things went better to plan, so we were able to raise that guidance recently. Then hit our EBITDA margins of greater than 40%.

If you look at the size of our company, we have 65 employees approximately. We have more revenue per employee than any other pharmaceutical company in industry. We have more value that we've created per employee than any other pharmaceutical in industry. I'm proud of that. That's great. But we have a lean operating model. Here is an idea of the pipeline. There are some other products that we're working on behind the scenes that aren't listed on this. KHINDIVI label expansion was really important. We had KHINDIVI approved a little over a year ago, and that is an oral solution of hydrocortisone for children that suffer from adrenocortical insufficiency. The market is for five It was developed for five and below. These children, if some of you have young kids, you got this oral aspirin, oral Tylenol, cough syrup, these types of things.

Trying to get a child to take a pill or something of that nature is extremely difficult. So we developed it with that population in mind. Then, almost, yeah, I guess I'll save my comments, but the FDA approved it for five and above. So we developed it for five and below, they approved it for five and above. That wasn't good. So we had to go back and change the formulation, reduce some of the excipients, and we did that. We actually did that even before we got the approval, because we knew that maybe they were going to have an issue with some of the excipients, so we were able to file that almost immediately upon approval. I'm looking forward to that product getting approved and launched in the first half of next year. We had a good dialogue with the agency.

We believe we have done exactly what they wanted to do, and that will end up with a very nice growth, and more importantly, patient access for KHINDIVI. Glyburide oral suspension. This is another aspect of how you can think about our strategy, where we will take products which are approved in Europe, and we will bring them into the United States. when it makes sense. For example, in Europe, it is called AMGLIDIA. The product is available in France. It is a very successful product. It is developed by two physicians. It is also available in several other countries in Europe. When we went to the agency on this, we thought, oh, gee, this is going to be a challenge. There are a number of reasons for that challenge, and we were really pleased to see that the FDA was fully supportive of this program.

They wanted to see this product brought to market. They saw there was an unmet need, and they saw that the efficacy and the safety looked, I believe, pretty good, and so they thought so as well. I think we are on track to file that, hopefully next month. It might slip into Q1, in early Q1, but this can be a 2027 launch, and that will be a meaningful product. Not a blockbuster product. I think we have said $20 million-$30 million in sales on that product, and that is fine. Again, this is for patients. Metabolic generic product, we have not stated that molecule for competitive reasons, but we expect to launch that in 2027. We also have, you look in 2028, we have ASN-001, ET-800.

We have got the Zeneo, which may end up being more of a, we will see how it works, but it is one of those programs that has been going on a little longer than I would like. I am hoping we are close to the finish line on that, and so on and so forth when you look at the little bit longer term projects in the pipeline. This slide I just get to pay a little bit of attention to because this is really, if I am on an elevator, this is what I would tell somebody. We have a three-pillar growth strategy. We grow existing products. I will start from the bottom. Commercial products, we have not obtained all of the market share. If you are looking at KHINDIVI and ALKINDI, for example, we are only like 10% into that market share.

That is why those products keep growing month-over-month. Every time I get a new sales report each week, we get more numbers on that. That goes also for a number of other products. INCRELEX, for example, when we took over the product, we had increased the product from like 60 to 100 patients, like literally within three months. But we have been growing it even since then. When we took over HEMANGEOL, we were hoping to get 80% of what the historical patients were, but we are now way over 100% of what the historical patients were on HEMANGEOL. So there is that organic growth of existing products, a lot of growth still left there. Secondly is our internal pipeline and development. I showed you some of those products we are developing internally. Some of those products were sort of life cycle management type approaches.

Our acquisitions and licensing, where we've gone and done probably more deals than most other companies in industry. We continue to do that. We expect to launch and to have another deal closed in the next, I'll just say the next three months or so. We're working on some late-stage assets that look very interesting and will add additional revenue to the company. From a commercial standpoint, right now we've got these four teams. We're going to move these teams around a little bit as we add in new disease states or new therapeutic call areas. Our Eton Cares program, I talked a little bit about that. We have meaningful partnerships with patient advocacy groups. That is so important for us, for the patients and the caregivers to know that we're there for them. We're typically looking for concentrated prescriber bases.

One thing I will say is when we are looking for licensing deals, we're looking for late-stage assets, meaning something that I can file within a 12-24 month period, something we can launch immediately, as if we acquired a product or something that's already under FDA review, and that's about where we look. We don't look for these early-stage clinical programs that are going to be 5+ years. That's just not what we do. We will continue to support not only the patients, but also to expand these different areas. The metabolic and infectious disease teams, there's a lot of rare diseases there that I think we can really continue to grow that one out. Right now, endocrinology is, we keep adding products to it, and that is also a very rich area for new treatments.

From a financial standpoint, I want to touch briefly on our SG&A infrastructure. SG&A is probably the lowest in industry with regards as comparison to our revenues. So we grow our revenue with a minimal increase in the SG&A. Our margins have continued to go up, and we've expanded our EBITDA to about 50%, which we had projected would be a couple of years away. We did that a lot sooner than what we expected. I think we just hit 49%, and that is So, being patient-focused doesn't mean you don't need to be fiscally fit. So we want to be fiscally fit. We have little to no debt. We've probably issued less equity over the nine years than most companies in our space. We rarely will issue equity unless it's in conjunction with a large transaction that adds a meaningful growth driver to the company.

I wanted to just touch on a couple of goals. We set these goals, I don't know, David, when did we set these goals?

David Krempa
Chief Business Officer, Eton Pharmaceuticals

March.

Sean Brynjelsen
CEO, Eton Pharmaceuticals

Okay, there we go. He's got it up there. Thanks for putting that there. We wanted to hit $200 million by the end of 2027. We just did that. We just reported $58 million in Q3 of 2026, so we're five quarters ahead of that. We wanted a 50% EBITDA margin by 2028. We reported 49%. I'm giving us credit for that one, and that's going to continue to grow with the coming quarters. Reaching $500 million of revenue by 2030. We haven't added the new date. I know what the date is. It's much earlier than what you're seeing on the screen, and that's partly in conjunction with the ASN deal, as it will help us hit those types of numbers. Better than expected relaunches, and obviously we've had really good, I guess, experiences with the FDA and with approvals and that type of thing.

That is it in a nutshell, and I will stop there. It looks like it came in at nine seconds left. Anybody have any questions? I am all ears. Yes.

Speaker 4

Yeah. Congratulations for the results in such a short period of time. Don't know very well your company, don't know very well your position in Europe, if you have any, if you have partners. Are you looking for partners? Can you elaborate on that?

Sean Brynjelsen
CEO, Eton Pharmaceuticals

Yeah. We do not typically go into Europe for a couple of reasons. One, we have most favored nation pricing obstacles. If we price something in the U.S., we have to price it the same in Europe. However, we can divest. For example, INCRELEX, we divested the European rights to a European partner. We divested it to STADA. If we are going to out-license, we typically would have to just offload it completely. Also in the U.S., the reimbursement and the pricing and the market opportunity allows us to have more products. If you look at the rest of the world, or even Europe, for example, we have 50% more rare disease products and therapies in the United States because of the economic incentives.

By not having the same economic incentives in Europe, I think that the governments are doing a disservice to these patients, which really could benefit from them. It is a small drop in the ocean when you look at the overall healthcare costs. If you do not look at pricing, but you look at the benefit to these kids, it really needs to be rethought, in my opinion, in Europe.

Speaker 4

Thank you.

Sean Brynjelsen
CEO, Eton Pharmaceuticals

Yeah. All right. Thank you, everyone, for your time.